The trademark application ELIXIRON was filed by ELIXIRON IMMUNOTHERAPEUTICS INC., a corporation established under the laws of Taiwan, Republic of China (the "Applicant"). Application under examination.
The application was filed in English (Spanish was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the treatment of Alzheimer’s disease
Pharmaceutical preparations for the treatment of vitiligo
Pharmaceutical preparations for the treatment of hemophagocytic syndrome
Pharmaceutical preparations for the treatment of alopecia
Pharmaceutical preparations for the treatment of ALS (Amyotrophic Lateral Sclerosis)
Pharmaceutical preparations for the treatment of Parkinson's disease
Pharmaceutical preparations for the treatment of neurodegenerative diseases
Pharmaceutical preparations for the treatment of immune diseases
Pharmaceutical preparations for the treatment of autoimmune diseases and disorders
Pharmaceutical preparations for the treatment of liver cancer
Pharmaceutical preparations for the treatment of cancer
Pharmaceutical preparations for suppressing tumors.
The mark was filed in class 42 with following description of goods:
Scientific research in the field of immunology
Scientific research in the field of neurodegeneration
Medical research services in the field of antibody
Conducting clinical trials for others
Clinical research services
Research and development of antibodies
Scientific and technological services, namely, scientific research, analysis, testing, in the field of medical reagent
Culturing of cells for others for scientific research purposes
Research and development of new products for others
Research and development of medicines
Technological research in the field of immunology
Scientific laboratory services
Scientific research
Scientific and technological research in the field of neurodegeneration
Technical consulting in the field of pharmaceutical studies
Technical consulting in the field of clinical research.